PENGARUH N-ASETIL SISTEIN ORAL TERHADAP PENURUNAN HsCRP PADA PASIEN PENYAKIT GINJAL KRONIS STADIUM V YANG MENJALANI CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)

Evi Nurhayatun

DOI: https://doi.org/10.23917/biomedika.v11i1.3941

Abstract

Inflammation and oxidative stress are risk factors of cardiovascular diseases among chronic kidney disease patients. There is increasing of HsCRP level in stage V CKD patients wih CAPD. N-Acetyl Cysteine(NAC) is a compounds containing thiol with antioxidant and anti-inflammatory effects. This research obejectives was to examine the effect of oral NAC in the decline of HsCRP level in stage V CKD patients with CAPD. This is an experimental research with Randomized Double Blind Control Trial, involving 30 patients CKD with CAPD Dr Moewardi Hospital and complete inclusion and exclusion criteria, divided 15 patients as a control group (placebo) and 15 patients as a treatment group of oral NAC. Examination of data research variables have been performed before and after 8 weeks treatment. The results were the level of HsCRP in control group before treatment and after treatment (15,76±42,79 vs 16,50±30,63). Level of HsCRP in treatment group before treatment and after treatment (29,53±76,52 vs 4,56±12,85) was decrease statistically significant with p< 0,05. The N-Acetyl Cysteine orally can decreased the level of HsCRP in stage V CKD patients with CAPD.

Keywords : N-Acetyl Cysteine, CAPD, HsCRP

References

Aguiar-Souto, P. Valero-González S, Domínguez JF. 2006. N-Acetylcysteine and Contrast Induced Nephropathy. N Engl J Med. 5 ;355(14) : Pp 1497-8

Borrás C, Esteve JM, Viña JR, Sastre J, Viña J, Pallardó FV. 2004. Glutathione regulates telomerase activity in 3T3 fibroblasts. J Biol Chem. 279 (33). Pp: 34332-5

Burkart J. 2004. Metabolic consequences of peritoneal dialysis. Semin Dial. 17(6). Pp: 498-504.

Caballo C. 2012. NFB in the development of endothelial activation and damage in uremia: an in vitro approach. PLoS ONE 7(8). Pp: 4337

Cachofeiro V dan David D. 2008. Oxidative Stress and Inflammation, a Link Between Chronic Kidney Disease and Cardiovascular Disease. Kidney Int. 74. Pp: 54-9.

DeFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. 2003. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis and cardiomyopathy ini patients undergoing long-term hemodialysis. Journal of American Medical Association. 290. Pp: 353-9.

Dekhuijzen PNR. 2004. Antioxidant Properties of N-Acetylcysteine: Their Relevance in Relation to Chronic Obstructive Pulmonary Disease. Eur Respir J. 23. Pp: 629–36.

Fresinius Medical Care. 2012. ESRD patients in 2011 : a global perspective. The Annual Fresenius Medical Care Market Survey, Pp: 4-10

Fontanet PR, Gómez L, Lartundo Q, Unzueta G, Fraile GM, Rodríguez T, et al. 2011. Markers of Inflammation Before and During Peritoneal Dialysis. Advances In Peritoneal Dialysis. Pp: 27.

Fortes PC, Versari PH, Stinghen AEM, Pecoits-Filto R. 2007. Controlling Inflammation in Peritoneal Dialysis: the Role of PD-related Factors as Potential Intervention Targets. Periton Dialysis Int. 27. Pp: 576-9.

Honda H. 2006. Serum albumin, C-Reactive Protein, Interleukin 6 and fetuin A as predictors of malnutrition, cardiovascular disease and mortality in patients with ESRD. Am J Kidney Dis. 47(1). Pp: 139-4811

Nanayakkara PWB dan Gaillard CAJM. 2010. Vascular Disease and Chronic Renal Failure: New Insights. Neth J Med. 68(1). Pp: 68

Nascimento MM, Suliman ME, Silva M, Chinaglia T, Marchioro J, Hayashi SY, et al. 2010. Effect of Oral N-Acetylcysteine Treatment on Plasma Inflammatory and Oxidative Stress Markers in Peritoneal Dialysis Patients: A Placebo-Controlled Study. Periton Dialysis Int. 30. Pp: 336–42.

Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, et al. 2004. Increased Prevalence of Oxidant Stress and Inflammation in Patients with Moderate to Severe Chronic Kidney Disease. Kidney Int. 65. Pp: 1009–16.

Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Norpoth M, et al. 2000. C reactive protein as marker of chronic inflammation in uremic patients. Blood Purificat. 21. Pp: 29-36

Santangelo F, Witko-Sarsat V, Drüeke T, Descamps-Latscha B. 2004. Restoring Glutathione as a Therapeutic Strategy in Chronic Kidney Disease. Nephrol Dial Transplant, 19. Pp: 1951–5.

Santoro A dan Mancini E. 2002. Cardiac Effects of Chronic Inflammation in Dialysis Patients. Nephrol Dial Transplant. 17(8). Pp: 10-15.

Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC. 2005. N-acetylcysteine Attenuates the Progression of Chronic Renal Failure. Kidney Int. 68. Pp: 2208–17.

Silverstein DM. 2009. Inflammation in Chronic Kidney Disease: Role in The Progression of Renal and Cardiovascular Disease. Pediatr Nephrol. 24. Pp:1445–52.

Article Metrics

Abstract view(s): 176 time(s)
PDF (Bahasa Indonesia): 123 time(s)

Refbacks

  • There are currently no refbacks.